Do you have probable Dementia with Lewy Bodies (DLB), Mild Cognitive Impairment with "high likelihood" DLB, or Parkinson's Disease Dementia (PDD)? You may be able to participate in an observational study to track your disease progression and promote future research.

We are collecting cerebral spinal fluid (CSF) from Normal Pressure Hydrocephaly (NPH) patients to generate a biosample research repository. This repository will be used to research CSF biomarkers for Alzheimer's disease that may enhance our ability to detect and monitor Alzheimer's disease diagnoses and progression.

The ASPIRE trial aims to study anticoagulant medications in patients who have had an intracerebral hemorrhage (bleeding in the brain) who also have atrial fibrillation (irregular heartbeats). Participants who agree to study participation will receive either Aspirin or Apixaban and followed for 12-36 months to see if they have any other strokes, and follow their general recovery after stroke.

This is a study being conducted at many sites across the US to evaluate patients who are older than 50 years old, who have sudden bleeding in the brain (intracerebral hemorrhage) while taking a statin medication. It is unclear if continuing to take a statin medication after this type of injury can increase the risk of another hemorrhage, stroke or cardiac event. This study will assign patients to 1 of 2 groups. One group will continue the statin medication they were taking previously. The other group will discontinue the statin medication. Both groups will be followed for 2 years to see if they have any additional medical events.

The purpose of this study is to evaluate both sporadic (not inherited), and familial (inherited), forms of frontotemporal lobar degeneration (FTLD). Patients include both those who have symptoms of FTLD and those who do not (yet have a family history involving FTLD). This is an observational study, meaning that there is no investigational treatment involved. We will be working with patients for up to a 5 year period to learn more about FTLD using a neurological exam, tests of memory, behavior, and judgement, MRI, and biospecimen collection (blood and/or CSF). This study involves genetic testing of the genes so far identified to be associated with FTLD. The overall goal is to help better understand FTLD, to better understand the genetics of FTLD, and to use the information we learn to guide improved patient care and potential drug development.

The purpose of the study is to identify certain processes following brain injury that may be associated with the risk of developing epilepsy.

This clinical trial aims to understand how well ALXN-C5IT works over a long time. We want to see if it can prevent relapses and help with disability, walking, and vision. We also want to know how patients feel about their health while using ALXN-C5IT.

The objective of the registry is to create a cohort of patients with NMOSD. This registry will be used for future research, as well as improvements to the diagnosis, treatment, and understanding of NMOSD.

The purpose of this study is to characterize the natural history of DRPLA patients using a variety of clinical and biomarker modalities and to identify genetic factors, biomarkers, and clinical measures that could predict disease progression.

This study will gather information about patients who are taking new medicines for Alzheimer's disease. We'll keep an eye on how these patients are doing in the long run, tracking things like how they're responding to treatment, what their overall health outcomes are like, and how safe these new treatments really are when used in the real world. The goal of this study is to get a better understanding of how these therapies actually work for a diverse group of people, not just the people who usually participate in clinical trials.